Lyka Labs (BOM:500259) EPS (Basic): ₹-2.82 (TTM As of Mar. 2026)


BOM:500259 Lyka Labs Ltd BOM:500259
49 GF Score
Price ₹69.26
GF Value ₹126.97
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lyka Labs EPS (Basic)?

Lyka Labs BOM:500259 -2.78% 49 EPS (Basic) is ₹-2.82 as of Mar. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 49/100 and a GF Value™ of ₹126.97 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Lyka Labs's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹-2.13. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-2.82.

Lyka Labs's EPS (Diluted) for the three months ended in Mar. 2026 was ₹-2.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-2.82.

Lyka Labs's EPS without NRI for the three months ended in Mar. 2026 was ₹-2.13. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -2.82.

During the past 12 months, Lyka Labs's average EPS without NRIGrowth Rate was -226.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was -10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Lyka Labs's highest 3-Year average EPS without NRI Growth Rate was 52.90% per year. The lowest was -166.50% per year. And the median was -0.70% per year.

Lyka Labs  (BOM:500259) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lyka Labs EPS (Basic) Related Terms

Lyka Labs EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Lyka Labs's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyka Labs EPS (Basic) Chart

Lyka Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.57 -4.63 -0.76 2.22 -2.81

Lyka Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.25 -0.94 0.00 -2.13
BOM:500259
49GF Score
Lyka Labs Ltd BOM:500259
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyka Labs EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lyka Labs's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-100.318-0)/35.700
=-2.81

Lyka Labs's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-76.068-0)/35.713
=-2.13

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹-2.82 mean?
Lyka Labs (BOM:500259) has a EPS (Basic) of ₹-2.82 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lyka Labs and its competitors.
Is Lyka Labs' EPS (Basic) too high?
Lyka Labs' current EPS (Basic) is ₹-2.82. Overall, Lyka Labs has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' EPS (Basic) compare to VRTX and REGN?
Lyka Labs' EPS (Basic) of ₹-2.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lyka Labs and its competitors. Lyka Labs's current EPS (Basic) is ₹-2.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.97, compared to a current price of ₹69.26 — trading 45.5% below its estimated fair value. The current EPS (Basic) is ₹-2.82. Lyka Labs' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current EPS (Basic) is ₹-2.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹69.26 is trading 45.5% below its estimated GF Value™ of ₹126.97. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • EPS (Basic): ₹-2.82
  • GF Value™: ₹126.97 vs. price of ₹69.26 (45.5% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
49GF Score

Get the complete analysis for BOM:500259

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹69.26
Price
₹126.97
GF Value